Microbot Medical Inc. (MBOT)
NASDAQ: MBOT · Real-Time Price · USD
2.370
-0.090 (-3.66%)
At close: Dec 5, 2025, 4:00 PM EST
2.390
+0.020 (0.83%)
After-hours: Dec 5, 2025, 7:55 PM EST
Microbot Medical Employees
Microbot Medical had 20 employees as of December 31, 2024. The number of employees decreased by 2 or -9.09% compared to the previous year.
Employees
20
Change (1Y)
-2
Growth (1Y)
-9.09%
Revenue / Employee
n/a
Profits / Employee
-$653,500
Market Cap
159.16M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MBOT News
- 9 days ago - Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System - GlobeNewsWire
- 4 weeks ago - Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S. - GlobeNewsWire
- 7 weeks ago - Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting - GlobeNewsWire
- 7 weeks ago - Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System - GlobeNewsWire
- 2 months ago - Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds - GlobeNewsWire
- 2 months ago - Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio - GlobeNewsWire
- 2 months ago - Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System - GlobeNewsWire
- 2 months ago - Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds - GlobeNewsWire